Trial Profile
A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2014
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Metformin; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 01 Feb 2014 Results published in the Drugs and Aging.
- 24 Mar 2010 Actual end date (Nov 2005) added as reported by ClinicalTrials.gov.
- 22 Oct 2005 New trial record.